References
- Oscier D, Fegan C, Hillmen P, et al.; Guidelines Working Group of the UK CLL Forum. British Committee for Standards in Haemotology. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004;125:294–317.
- Howlader N, Noone AM, Krapcho M, et al., editors. SEER Cancer Statistics Review, 1975–2010 [based on November 2012 SEER data submission, posted to the SEER web site, April 2013]. Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2010/
- Redaelli A, Laskin BL, Stephens JM, et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur J Cancer Care 2004;13:279–287.
- Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362–371.
- Xu W, Miao KR, Zhu DX, et al. Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia. Int J Cancer 2011;128:2192–2201.
- Teeling JL, French RR, Cragg MS, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793–1800.
- Wierda WG, Kipps TJ, Mayer J, et al. Final analysis from the international trial of single-agent ofatumumab in patients with fludarabine-refractory chronic lymphocytic leukemia. Blood 2010;116(Suppl. 1): Abstract 921.
- Wierda WG, Kipps TJ, Mayer J, et al.; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
- Hallek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Lymphoma. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 Guidelines. Blood 2008;111:5446–5456.